Physician profile

Roxana Naderi

Internal Medicine · Roseville, CA

NPI 1871936070

$278.26

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$88.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $92.84 2021-2024
Abbott Laboratories $68.03 2022-2023 Freestyle Libre 2
Amgen INC. $33.60 2022-2024 Evenity, Prolia
Dynavax Technologies Corporation $25.42 2022
Biohaven Pharmaceuticals, INC. $19.40 2021
Astrazeneca Pharmaceuticals LP $14.76 2023 Farxiga
Nestle Healthcare Nutrition INC. $13.10 2021
Lupin INC. $11.11 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roxana Naderi

$278.26

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/2665079/roxana-naderi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.